search
Back to results

The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Primary Purpose

Arrhythmogenic Right Ventricular Cardiomyopathy

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
80 lead ECG
Sponsored by
The Leeds Teaching Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Arrhythmogenic Right Ventricular Cardiomyopathy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients with a confirmed diagnosis of arrhythmogenic right ventricular cardiomyopathy who are being followed up in the cardiology clinic

Exclusion Criteria:

  • Inability to consent
  • Pacing dependent patients
  • Other concomitant cardiag disease e.g. coronary artery disease
  • Atrial fibrillation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    Patient

    Healthy volunteers

    Arm Description

    Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

    Aged and gender matched healthy controls.

    Outcomes

    Primary Outcome Measures

    QRS wave dispersion in an ECG
    The difference in QRS wave dispersion between the right and left ventricular leads

    Secondary Outcome Measures

    Full Information

    First Posted
    November 11, 2014
    Last Updated
    May 18, 2015
    Sponsor
    The Leeds Teaching Hospitals NHS Trust
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02291393
    Brief Title
    The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
    Official Title
    The Role of High Density Surface Cardiac Electrographic Mapping in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy :A Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    August 2012 (undefined)
    Primary Completion Date
    October 2012 (Actual)
    Study Completion Date
    October 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    The Leeds Teaching Hospitals NHS Trust

    4. Oversight

    5. Study Description

    Brief Summary
    The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition. This pilot would form the basis of a much larger clinical trial to test the utility of this novel diagnostic tool.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Arrhythmogenic Right Ventricular Cardiomyopathy

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    20 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Patient
    Arm Type
    Other
    Arm Description
    Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
    Arm Title
    Healthy volunteers
    Arm Type
    Other
    Arm Description
    Aged and gender matched healthy controls.
    Intervention Type
    Device
    Intervention Name(s)
    80 lead ECG
    Primary Outcome Measure Information:
    Title
    QRS wave dispersion in an ECG
    Description
    The difference in QRS wave dispersion between the right and left ventricular leads
    Time Frame
    5 minutes

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients with a confirmed diagnosis of arrhythmogenic right ventricular cardiomyopathy who are being followed up in the cardiology clinic Exclusion Criteria: Inability to consent Pacing dependent patients Other concomitant cardiag disease e.g. coronary artery disease Atrial fibrillation

    12. IPD Sharing Statement

    Learn more about this trial

    The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

    We'll reach out to this number within 24 hrs